[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100584839":3},{"organization":4,"armGroups":7,"interventions":7,"overallOfficials":8,"centralContacts":13,"locations":19,"responsibleParty":40,"collaborators":42,"id":46,"slug":47,"hasResults":48,"nctId":49,"briefTitle":50,"officialTitle":50,"acronym":51,"eligibilityCriteria":52,"healthyVolunteers":48,"sex":53,"minAge":54,"maxAge":7,"enrollmentInfo":55,"targetDuration":7,"studyType":58,"phases":7,"briefSummary":59,"conditions":60,"keywords":7,"overallStatus":21,"whyStopped":7,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":63,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":70,"locationsCount":71},{"fullName":5,"class":6},"Ottawa Hospital Research Institute","OTHER",null,[9],{"name":10,"affiliation":11,"role":12},"Marc Carrier, MD","Ottawa Hospital","PRINCIPAL_INVESTIGATOR",[14],{"name":15,"role":16,"phone":17,"phoneExt":7,"email":18},"Kristina Vrotniakaite-Bajerciene, MD","CONTACT","613-737-8899","kvrotniakaite@toh.ca",[20],{"facility":5,"status":21,"city":22,"state":23,"zip":24,"country":25,"countryCode":26,"cosmosGeoPoint":27,"geoPoint":32,"contacts":33},"RECRUITING","Ottawa","Ontario","K1H8L6","Canada","CA",{"type":28,"coordinates":29},"Point",[30,31],-75.69812,45.41117,{"lat":31,"lon":30},[34,37,38],{"name":35,"role":16,"phone":7,"phoneExt":7,"email":36},"Heather Langlois","hlanglois@ohri.ca",{"name":10,"role":12,"phone":7,"phoneExt":7,"email":7},{"name":15,"role":39,"phone":7,"phoneExt":7,"email":7},"SUB_INVESTIGATOR",{"type":41,"investigatorFullName":7,"investigatorTitle":7,"investigatorAffiliation":7,"oldNameTitle":7,"oldOrganization":7},"SPONSOR",[43],{"name":44,"class":45},"Canadian Institutes of Health Research (CIHR)","OTHER_GOV","100584839","development-of-a-risk-stratification-score-for-recurrent-venous-thromboembolism-and-treatment-related-clinically-relevant-bleeding-in-patients-with-cancer-associated-thrombosis-100584839",false,"NCT06894576","Development of a Risk Stratification Score for Recurrent Venous Thromboembolism and Treatment-related Clinically Relevant Bleeding in Patients With Cancer-associated Thrombosis","CAN-CATCH","Inclusion Criteria:\n\n* Objectively documented distal and\u002For proximal DVT of the limb (upper or lower extremity) and\u002For PE, splanchnic vein thrombosis and\u002For cerebral sinus vein thrombosis in presence of active cancer of all types\n* Intended treatment of CAT for at least 6 months with parenteral or oral anticoagulants at therapeutic dosing.\n* Estimated life expectancy \\> 6 months\n* Willingness to give an informed consent\n* Age ≥ 18 years\n\nExclusion Criteria:\n\n* Unusual site CAT (gonadal vein thrombosis, ovarian vein thrombosis, retinal vein thrombosis)\n* Superficial vein thrombosis\n* Refusal of informed consent \\> 72 hrs of anticoagulants\n* Age \\\u003C 18 years old","ALL","18 Years",{"count":56,"type":57},1000,"ESTIMATED","OBSERVATIONAL","The objective of this study is to prospectively develop a risk assessment model (RAM) that accurately identifies anticoagulated cancer-associated thrombosis (CAT) patients at low- and high-risk of recurrent venous thromboembolism (VTE) and clinically relevant bleeding within 6 months following the CAT diagnosis and to create a biobank of plasma and whole blood samples for further translational research in cancer genetics and hemostasis.",[61],"Cancer-associated Thrombosis","2025-03-18",{"date":64,"type":65},"2025-03-25","ACTUAL",{"date":67,"type":65},"2024-12-03",{"date":69,"type":57},"2027-12",{"name":5,"class":6},1]